Ligand Pharmaceuticals Enters New Loan Agreement
Ticker: LGNZZ · Form: 8-K · Filed: Jul 10, 2024 · CIK: 886163
| Field | Detail |
|---|---|
| Company | Ligand Pharmaceuticals Inc (LGNZZ) |
| Form Type | 8-K |
| Filed Date | Jul 10, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $75,000,000, $125,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: debt, financing, material-agreement
Related Tickers: LGND
TL;DR
Ligand just took out a new loan, details to come.
AI Summary
On July 8, 2024, Ligand Pharmaceuticals Inc. entered into a material definitive agreement, specifically a loan and security agreement with an unnamed lender. This agreement creates a direct financial obligation for Ligand, the details of which are not fully disclosed in this filing.
Why It Matters
This filing indicates Ligand Pharmaceuticals has taken on new debt, which could impact its financial leverage and future investment capacity.
Risk Assessment
Risk Level: medium — The creation of a new financial obligation introduces leverage and potential repayment risks for the company.
Key Players & Entities
- Ligand Pharmaceuticals Inc. (company) — Registrant
- July 8, 2024 (date) — Date of earliest event reported
- 0000886163-24-000059 (accession_number) — Filing accession number
FAQ
What is the specific amount of the loan and the terms of the security agreement?
The filing does not disclose the specific dollar amount of the loan or the detailed terms of the security agreement, only that a material definitive agreement in the form of a loan and security agreement was entered into.
Who is the lender in this loan and security agreement?
The identity of the lender is not disclosed in this Form 8-K filing.
What is the purpose of this new financial obligation for Ligand Pharmaceuticals?
The purpose of the loan and security agreement is not specified in this filing.
When was the loan and security agreement officially entered into?
The agreement was entered into on July 8, 2024, which is the date of the earliest event reported.
What are the implications of this 'direct financial obligation' for Ligand's balance sheet?
The filing states that this agreement creates a direct financial obligation, implying it will appear as a liability on Ligand's balance sheet, increasing its debt.
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 12.7 · Accepted 2024-07-10 16:02:22
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share LGND The Nasdaq Global Market
- $75,000,000 — e revolving credit facility amount from $75,000,000 to $125,000,000. The above summary of
- $125,000,000 — dit facility amount from $75,000,000 to $125,000,000. The above summary of the Amendment do
Filing Documents
- lgnd-20240708.htm (8-K) — 24KB
- 0000886163-24-000059.txt ( ) — 146KB
- lgnd-20240708.xsd (EX-101.SCH) — 2KB
- lgnd-20240708_lab.xml (EX-101.LAB) — 22KB
- lgnd-20240708_pre.xml (EX-101.PRE) — 13KB
- lgnd-20240708_htm.xml (XML) — 3KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On July 8, 2024, Ligand Pharmaceuticals Incorporated (the "Company") entered into the first amendment (the "Amendment") to the revolving credit facility ("Credit Agreement"), dated as of October 12, 2023, among the Company, certain of its subsidiaries, as Guarantors (as defined therein), the Lenders (as defined therein), and Citibank, N.A., as Administrative Agent, Swingline Lender and L/C Issuer (each as defined therein). The Amendment amends the Credit Agreement to, among other things, increase the aggregate revolving credit facility amount from $75,000,000 to $125,000,000. The above summary of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment which will be filed as an exhibit to Ligand's Quarterly Report on From 10-Q to be filed with respect to the quarter ended June 30, 2024. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information set forth in Item 1.01 is incorporated herein by reference.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIGAND PHARMACEUTICALS INCORPORATED Date: July 10, 2024 By: /s/ Andrew Reardon Name: Andrew Reardon Title: Chief Legal Officer and Secretary